Confirmatory Overall Survival Analysis of CLEOPATRA


Confirmatory Overall Survival Analysis of CLEOPATRA
Slides from a presentation at SABCS 2012 and transcribed comments from a recent interview with Edith A Perez, MD (1/17/13)
Swain SM et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: A randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2012;Abstract P5-18-26.

Dr Perez is Deputy Director at Large of the Mayo Clinic Cancer Center, Group Vice Chair of the Alliance of Clinical Trials in Oncology and Serene M and Frances C Durling Professor of Medicine at the Mayo Clinic in Jacksonville, Florida.